|I. MODIFIED AGREEMENTS|
Change from original
Eli Lilly and Co.
A District Court jury ruled Lilly's Evista and Xigris drugs infringed Ariad patents on treating disease by regulating NF-(kappa)B cell-signaling
Ariad was awarded damages of $65.2M, representing a royalty rate of 2.3% and said it would get 2.3% of U.S. sales of the drugs through 2019; Lilly plans to challenge the verdict (5/4)
Cytogen bought out Berlex's royalty interest in Quadramet, an approved oncology product
Berlex gets a payment of $6M and 623,441 Cytogen shares that were valued at about $2M; it also could get about $8.35M in sales-based milestone payments (5/8)
# The information in the chart does not cover agreements between biotech companies or agricultural agreements.
* Private companies are indicated with an asterisk.
Unless otherwise noted, stock symbols listed are on the Nasdaq market.